Anna Rodonski, PA
Medical · New Haven, CTNPI 1558306340
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,025 of the $6,833 with a category attached, or 73.5%. E.r. Squibb & Sons, L.L.C. accounts for 76.9% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2021 at $4,818 and has fallen 99.6% since, to $17 in 2025. Among medical clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 71 payments — averaging $96.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$5K
- Abiomed$322
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$229
- Amgen$160
- Boehringer Ingelheim$152
- Johnson & Johnson$136
- plus $581 from 16 others
What the payments were for
- Consulting fees$5,02574%
- Food & beverage$1,80826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 13 | $5,253 |
| Abiomed | 2 | $322 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $229 |
| Amgen | 9 | $160 |
| Boehringer Ingelheim | 6 | $152 |
| Johnson & Johnson | 7 | $136 |
| Pfizer | 5 | $84 |
| Abbott | 3 | $66 |
| Bayer | 3 | $57 |
| AstraZeneca | 3 | $55 |
| Novo Nordisk | 2 | $44 |
| Heartflow, Inc. | 2 | $40 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $37 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $31 |
| Recor Medical Inc | 1 | $26 |
| Atricure, Inc. | 1 | $25 |
| Ancora Heart, Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,833 in reported general payments places this provider in the 90th percentile of 592 medical providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 304 | $2,494,208 |
| VyndamaxTafamidis | 16 | $371,850 |
| VyndaqelTafamidis Meglumine | 14 | $305,787 |
| JardianceEmpagliflozin | 162 | $112,713 |
| EliquisApixaban | 51 | $53,868 |
| Repatha SureclickEvolocumab | 25 | $24,754 |
| FarxigaDapagliflozin Propanediol | 25 | $21,518 |
| EntrestoSacubitril/Valsartan | 17 | $15,553 |
| VascepaIcosapent Ethyl | 11 | $5,521 |
| Ranolazine ErRanolazine | 13 | $2,856 |
| Torsemide | 95 | $1,979 |
| Metoprolol Succinate | 125 | $1,788 |
| Atorvastatin Calcium | 131 | $1,507 |
| Ezetimibe | 75 | $1,311 |
| Spironolactone | 128 | $1,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $5,253 | $2,494,208304 claims |
| PfizerVyndamax, Vyndaqel, Eliquis | $84 | $731,50681 claims |
| Boehringer IngelheimJardiance | $152 | $112,713162 claims |
| AstraZenecaFarxiga | $55 | $21,51825 claims |
| NovartisEntresto | $15 | $15,55317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 592 medical providers in Connecticut.
Other medical in New Haven
- Gregory RauNew Haven$211K
- Ryan DonovanNew Haven$75K
- Audrey LastraNew Haven$13K
- Melissa FairbairnNew Haven$11K
- Kyla RedwoodNew Haven$9K
- Michael SchultzNew Haven$5K
- Breana BrehmNew Haven$5K
- Andrew TurczakNew Haven$5K
- Shilpa DesaiStamford$215K
- John JasinskiNorwalk$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.